Type 1 Diabetes Drugs Market by Product and Geography - Forecast and Analysis 2021-2025

Executive Summary

Market Landscape

• Market ecosystem
• Market characteristics
• Value chain analysis

Market Sizing

• Market definition
• Market segment analysis
• Market size 2020
• Market outlook: Forecast for 2020 - 2025

Five Forces Analysis

• Five Forces Summary
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition

Market Segmentation by Product

• Market segments
• Comparison by Product
• Long-acting insulins - Market size and forecast 2020-2025
• Rapid-acting insulins - Market size and forecast 2020-2025
• Pre-mixed insulins - Market size and forecast 2020-2025
• Non-insulin drugs - Market size and forecast 2020-2025
• Market opportunity by Product

Customer Landscape

Geographic Landscape

• Geographic segmentation
• Geographic comparison
• North America - Market size and forecast 2020-2025
• Europe - Market size and forecast 2020-2025
• Asia - Market size and forecast 2020-2025
• ROW - Market size and forecast 2020-2025
• Key leading countries
• Market opportunity by geography
• Market drivers
• Market challenges
• Market trends

Vendor Landscape

• Overview
• Vendor landscape
• Landscape disruption

Vendor Analysis

• Vendors covered
• Market positioning of vendors
• Actiza Pharmaceutical Pvt. Ltd.
• Astellas Pharma Inc.
• AstraZeneca Plc
• Biocon Ltd.
• Bristol-Myers Squibb Co.
• Eli Lilly and Co.
• MannKind Corp. 
• Novo Nordisk AS
• Sanofi SA
• Viatris Inc.

Appendix

• Scope of the report
• Currency conversion rates for US$
• Research methodology
• List of abbreviations